Group 1: Company Performance - The company achieved stable growth in the first half of 2017, with a focus on its established business plan [2] - The biological products, particularly recombinant growth hormone, continued to grow rapidly due to high quality and effectiveness in treating children's growth issues [2] - Increased awareness and economic capability among residents contributed to the rising demand for growth hormone treatments [2] Group 2: Product Development and Marketing Strategies - The company is adapting its marketing strategies to promote interferon in various antiviral applications, leading to significant growth in external applications [3] - The revenue share from external interferon products has increased, contributing to a slight overall growth in interferon sales in the first half of the year [3] - The company is advancing the research and development of peptide formulations to enhance sales performance [3] Group 3: Research and Clinical Trials - The company is conducting clinical trials for monoclonal antibody drugs targeting Her-2 and PD-1, with promising prospects for broad anti-tumor efficacy [3] - The company is actively preparing for clinical submissions related to CAR-T technology, focusing on blood cancers and solid tumors [3]

证券代码：300009 证券简称：安科生物 安徽安科生物工程（集团）股份有限公司 投资者关系活动记录表 编号：2019-001 | --- | --- | --- | |-----------------------------|--------------------------------|------------------------------------------------------| | | | | | 投 资 者 关 系 活 动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参 与 单 位 名 称 及 | 川财证券 吴**；创金合信基金 曹 | ** ；创金合信基金 皮 ** | | 人员姓名 | | | | 时间 | 2019 年 7 月 23 日 | 09:30 | | 地点 | 公司 A 座 902 会议室 | | | 上 市 公 司 接 待 人 员姓名 | | 董事会秘书、副总经理姚建平；证券事务 ...

证券代码：300009 证券简称：安科生物 安徽安科生物工程（集团）股份有限公司 投资者关系活动记录表 编号：2017-005 | --- | --- | --- | |--------------|-------------------------------|--------------------------------------------------------| | | | | | 投资者关系活 | √ 特定对象调研 | □ 分析师会议 | | 动类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称 | 中信建投 程*；宏鼎财富管理 梁 | ** ；盛盈资本 袁 ** ；鑫富越 | | 及人员姓名 | 资管 张 * | | | 时间 | 2017 年 10 月 30 | 日 15:00 | | 地点 | 公司 A 座 902 会议室 | | | 上市公司接待 | | | | 人员姓名 | | 董事会秘书、副总经理姚建平，证券事务代表李坤 | | 投资者关系 ...

R&D Progress - The company has two specifications for recombinant human growth hormone water injection: 4IU/1.33mg/1ml and 10IU/3.33mg/1ml, with plans to increase product specifications based on market demand [3] - HER-2 monoclonal antibody is currently in Phase III clinical trials, with patient enrollment completed and data preparation underway for production application [3] - The recombinant PD-1 humanized monoclonal antibody is in Phase I/II clinical trials, while VEGF monoclonal antibody is undergoing Phase III clinical trials [3] - The PEG-recombinant human growth hormone injection has completed clinical trials and is currently undergoing production line modifications in preparation for production application [3] Market Development - The company aims to strengthen its domestic forensic DNA business while actively expanding into international forensic DNA markets [4] - Future plans include entering the clinical DNA testing and rapid DNA testing for crime scenes to identify new profit growth points [4] Market Demand - The market for recombinant human growth hormone is experiencing steady growth due to increasing demand, heightened awareness among families of children with growth deficiencies, a rise in pediatricians, improved economic capacity, and deeper marketing channels [4]

证券代码：300009 证券简称：安科生物 安徽安科生物工程（集团）股份有限公司 投资者关系活动记录表 编号：2017-006 | --- | --- | --- | |--------------|-------------------------------|----------------------------------------------------------| | | | | | 投资者关系活 | √ 特定对象调研 | □ 分析师会议 | | 动类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称 | | 浙商证券 蒋*；安信证券 崔**、梁**；永赢基金 安**；中泰证 | | 及人员姓名 | | 券 赵*；复翼资本 姜*；浙商资管 卢**，戴*，李 ** ；泰达宏 | | | 利 周 ** ；弘尚资产 何 | ** ；东方证券 左**；华安基金 袁**；太 | | | | 平资产 许**；西部自营 陈*；东兴证券 祁 * | | 时间 | 201 ...

Group 1: Company Overview and Investor Relations - Anke Bioengineering (Group) Co., Ltd. is engaged in investor relations activities, including targeted research and discussions with institutional investors [2][4]. - The meeting took place on November 14, 2017, at the company's conference hall, attended by key executives including the chairman and vice presidents [4][6]. Group 2: CAR-T Cell Immunotherapy - The company focuses on CD-19 CAR-T cell immunotherapy, which has shown a complete response (CR) rate exceeding 80% in difficult-to-treat relapsed patients [5]. - The market potential for CD-19 CAR-T therapy is significant, with an estimated 112,000 deaths annually from blood cancers in China, including approximately 57,000 from B-cell lymphoblastic leukemia and non-Hodgkin lymphoma [5]. Group 3: Growth Hormone Sales and Market Expansion - The rapid growth in sales of recombinant human growth hormone is attributed to expanded market coverage and targeted promotional activities [6]. - The two-child policy in China is expected to increase the patient base and market potential for growth hormone treatments [6]. Group 4: R&D and Product Development - The company is actively developing a range of innovative drugs, with a focus on growth hormone products and CAR-T therapies [7]. - Current projects include long-acting growth hormone injections and monoclonal antibodies, with several products in various stages of clinical trials [7][8]. Group 5: Clinical Trial Requirements - The approval process for CAR-T therapies in China is expected to require two phases of clinical trials, although existing clinical data may provide supportive evidence [8]. - The company is prioritizing the stability of production processes and quality assurance systems in preparation for regulatory submissions [8].

证券代码：300009 证券简称：安科生物 安徽安科生物工程（集团）股份有限公司 投资者关系活动记录表 编号：2019-002 | --- | --- | --- | |-----------------------------|--------------------------------------|------------------------------------------------------| | | | | | | | | | 投 资 者 关 系 活 动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 □ 新闻发布会 | □ 业绩说明会 □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参 与 单 位 名 称 及 | | 光大资管 赵**；新华基金 王*；兴全基金 隋*；中泰证券 | | 人员姓名 | 赵 * | | | | | | | 时间 | 2019 年 9 月 12 日 13:30 | | | 地点 | 公司 A 座 1002 会议室 | | | 上 市 公 司 接 待 人 员姓名 | | 董事会 ...

证券代码：300009 证券简称：安科生物 安徽安科生物工程（集团）股份有限公司 投资者关系活动记录表 编号：2018-001 | --- | --- | --- | |--------------|---------------------------------|------------------------------------------------------------| | | | | | 投资者关系活 | □ 特定对象调研 | □ 分析师会议 | | 动类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | √ 其他 （ 现场交流与网络直播 ） | | | 参与单位名称 | | 参加现场活动：证券时报、中国证券报、西南证券、中信证券、 | | 及人员姓名 | | 方正证券、东吴证券、国泰君安证券、渤海证券、太平洋证券、招 | | | | 商证券、财通证券、华安证券、国信证券、国联证券、万联证券、 | | | | 华金证券、华创证券、中天国证券、国都证券、上海希瓦资产管 | | | | 理有限公司、浙江中大投资集团有 ...

证券代码：300009 证券简称：安科生物 安徽安科生物工程（集团）股份有限公司 投资者关系活动记录表 编号：2018-002 | --- | --- | --- | |-----------------------------|--------------------------------------|---------------------------------------------------------| | | | | | 投 资 者 关 系 活 动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参 与 单 位 名 称 及 | 浙商证券 陈**；投资快报 吴*；沈*；汤 | *；谬* ；谢*；罗 * | | 人员姓名 | | | | | *；李**；周* | ；王*；周*；田 *；麦** | | 时间 | 2018 年 8 月 29 日 | 16:00 | | 地点 | 公司 A 座 902 会议室 | | ...

证券代码：300009 证券简称：安科生物 安徽安科生物工程（集团）股份有限公司 投资者关系活动记录表 编号：2020-003 | --- | --- | --- | |-------------------------------|--------------------------------|-------------------------------------------------------| | | | | | | | | | 投 资 者 关 系 活 动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参 与 单 位 名 称 及 人员姓名 | | 国盛证券 杨**；建信养老金 蒋*；东方证券资管 解*；湘财 | | | 基金 徐 ** | | | 时间 | 2020 年 11 月 9 日 | 15:00 | | 地点 | 公司 A 座 902 会议室 | | | 上 市 公 司 接 待 人 员姓名 | | 董事 ...